{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:51:01Z","timestamp":1791337861310,"version":"4.3.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Avadel Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40263-024-01150-8","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T04:30:18Z","timestamp":1742531418000},"page":"37-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Use of \u03b3-Hydroxybutyrate: History and Clinical Utility of Oxybates and Considerations of Once- and Twice-Nightly Dosing in Narcolepsy"],"prefix":"10.1007","volume":"39","author":[{"given":"Thomas","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.5664\/jcsm.8482","volume":"16","author":"J Acquavella","year":"2020","unstructured":"Acquavella J, Mehra R, Bron M, et al. Prevalence of narcolepsy and other sleep disorders and frequency of diagnostic tests from 2013\u20132016 in insured patients actively seeking care. J Clin Sleep Med. 2020;16:1255\u201363.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","volume":"15","author":"CLA Bassetti","year":"2019","unstructured":"Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy-clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15:519\u201339.","journal-title":"Nat Rev Neurol"},{"key":"1150_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/sleep\/30.1.13","volume":"30","author":"WT Longstreth Jr","year":"2007","unstructured":"Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep. 2007;30:13\u201326.","journal-title":"Sleep"},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100.","journal-title":"Nat Rev Dis Primers"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5664\/jcsm.6494","volume":"13","author":"K Maski","year":"2017","unstructured":"Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13:419\u201325.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","volume":"20","author":"CE Mahoney","year":"2019","unstructured":"Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20:83\u201393.","journal-title":"Nat Rev Neurosci"},{"key":"1150_CR7","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654\u201362.","journal-title":"N Engl J Med"},{"key":"1150_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1113\/jphysiol.2006.108266","volume":"574","author":"X Xie","year":"2006","unstructured":"Xie X, Crowder TL, Yamanaka A, et al. GABA(B) receptor-mediated modulation of hypocretin\/orexin neurones in mouse hypothalamus. J Physiol. 2006;574:399\u2013414.","journal-title":"J Physiol"},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1208\/s12248-020-00543-z","volume":"23","author":"MA Felmlee","year":"2021","unstructured":"Felmlee MA, Morse BL, Morris ME. Gamma-hydroxybutyric acid: pharmacokinetics, pharmacodynamics, and toxicology. AAPS J. 2021;23:22.","journal-title":"AAPS J"},{"key":"1150_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0317167100119304","volume":"6","author":"R Broughton","year":"1979","unstructured":"Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6:1\u20136.","journal-title":"Can J Neurol Sci"},{"key":"1150_CR11","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. NDA 21-196 Xyrem (sodium oxybate) oral solution approval letter. Rockville: US Food and Drug Administration; 2002."},{"key":"1150_CR12","unstructured":"US Food & Drug Administration. Memorandum: Decision to waive the requirement for a single, shared system REMS for sodium oxybate oral solution. 2017. https:\/\/www.fda.gov\/media\/102913\/download. Accessed 16 Oct 2024."},{"key":"1150_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/jcph.767","volume":"57","author":"CM White","year":"2017","unstructured":"White CM. Pharmacologic, pharmacokinetic, and clinical assessment of illicitly used gamma-hydroxybutyrate. J Clin Pharmacol. 2017;57:33\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1150_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0028-3908(64)90074-7","volume":"3","author":"H Laborit","year":"1964","unstructured":"Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3:433\u201351.","journal-title":"Int J Neuropharmacol"},{"key":"1150_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00000542-196411000-00007","volume":"25","author":"M Helrich","year":"1964","unstructured":"Helrich M, McAslan TC, Skolnik S, Bessman SP. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology. 1964;25:771\u20135.","journal-title":"Anesthesiology"},{"key":"1150_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1213\/00000539-196211000-00011","volume":"41","author":"M Blumenfeld","year":"1962","unstructured":"Blumenfeld M, Suntay RG, Harmel MH. Sodium gamma-hydroxybutyric acid: a new anesthetic adjuvant. Anesth Analg. 1962;41:721\u20136.","journal-title":"Anesth Analg"},{"key":"1150_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004311-196900710-00007","volume":"7","author":"MD Vickers","year":"1969","unstructured":"Vickers MD. Gammahydroxybutyric acid. Int Anesthesiol Clin. 1969;7:75\u201389.","journal-title":"Int Anesthesiol Clin"},{"key":"1150_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1208\/s12248-008-9035-6","volume":"10","author":"ME Morris","year":"2008","unstructured":"Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008;10:311\u201321.","journal-title":"AAPS J"},{"key":"1150_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0014-2999(01)01334-6","volume":"428","author":"MA Carai","year":"2001","unstructured":"Carai MA, Colombo G, Brunetti G, et al. Role of GABA(B) receptors in the sedative\/hypnotic effect of gamma-hydroxybutyric acid. Eur J Pharmacol. 2001;428:315\u201321.","journal-title":"Eur J Pharmacol"},{"key":"1150_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1254\/jphs.FP0071487","volume":"106","author":"MA Carai","year":"2008","unstructured":"Carai MA, Lobina C, Maccioni P, et al. Gamma-aminobutyric acidB (GABAB)-receptor mediation of different in vivo effects of gamma-butyrolactone. J Pharmacol Sci. 2008;106:199\u2013207.","journal-title":"J Pharmacol Sci"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1111\/j.1460-9568.2003.03013.x","volume":"18","author":"K Kaupmann","year":"2003","unstructured":"Kaupmann K, Cryan JF, Wellendorph P, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci. 2003;18:2722\u201330.","journal-title":"Eur J Neurosci"},{"key":"1150_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1124\/mol.112.078154","volume":"82","author":"BL Morse","year":"2012","unstructured":"Morse BL, Vijay N, Morris ME. gamma-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol. 2012;82:226\u201335.","journal-title":"Mol Pharmacol"},{"key":"1150_CR23","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1073\/pnas.1204376109","volume":"109","author":"N Absalom","year":"2012","unstructured":"Absalom N, Eghorn LF, Villumsen IS, et al. alpha4betadelta GABA(A) receptors are high-affinity targets for gamma-hydroxybutyric acid (GHB). Proc Natl Acad Sci USA. 2012;109:13404\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1150_CR24","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/0024-3205(82)90624-5","volume":"30","author":"J Benavides","year":"1982","unstructured":"Benavides J, Rumigny J, Bourguignon J, et al. High affinity binding site for \u03b3-hydroxybutyric acid in rat brain. Life Sci. 1982;30:953\u201361.","journal-title":"Life Sci"},{"key":"1150_CR25","first-page":"23","volume":"7","author":"R Broughton","year":"1980","unstructured":"Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep\/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci. 1980;7:23\u201331.","journal-title":"Can J Neurol Sci"},{"key":"1150_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/sleep\/9.1.159","volume":"9","author":"J Montplaisir","year":"1986","unstructured":"Montplaisir J, Godbout R. Nocturnal sleep of narcoleptic patients: revisited. Sleep. 1986;9:159\u201361.","journal-title":"Sleep"},{"key":"1150_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1570159X13666141210215423","volume":"13","author":"FP Busard\u00f2","year":"2015","unstructured":"Busard\u00f2 FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13:47\u201370.","journal-title":"Curr Neuropharmacol"},{"key":"1150_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1196\/annals.1369.065","volume":"1074","author":"S Abanades","year":"2006","unstructured":"Abanades S, Farre M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006;1074:559\u201376.","journal-title":"Ann N Y Acad Sci"},{"key":"1150_CR29","doi-asserted-by":"crossref","unstructured":"Seiden D, Tyler C, Dubow J. Pharmacokinetics of FT218, a once-nightly sodium oxybate formulation in healthy adults. Clin Ther. 2021;43:672e1-e14.","DOI":"10.1016\/j.clinthera.2021.01.017"},{"key":"1150_CR30","unstructured":"United States Congress. H.R.2130\u2014Hillory J. Farias and Samantha Reid Date-Rape Drug Prohibition Act of 2000. 2000. https:\/\/www.congress.gov\/bill\/106th-congress\/house-bill\/2130. Accessed 2024."},{"key":"1150_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1310\/hpj4806-473","volume":"48","author":"M Gabay","year":"2013","unstructured":"Gabay M. The federal controlled substances act: schedules and pharmacy registration. Hosp Pharm. 2013;48:473\u20134.","journal-title":"Hosp Pharm"},{"key":"1150_CR32","first-page":"278","volume":"3","author":"G Tunnicliff","year":"2002","unstructured":"Tunnicliff G, Raess BU. Gamma-hydroxybutyrate (orphan medical). Curr Opin Investig Drugs. 2002;3:278\u201383.","journal-title":"Curr Opin Investig Drugs"},{"key":"1150_CR33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/sleep\/25.8.42","volume":"25","author":"US Xyrem Multicenter Study Group","year":"2002","unstructured":"US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25:42\u20139.","journal-title":"Sleep"},{"key":"1150_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.sleep.2003.11.002","volume":"5","author":"US Xyrem Multicenter Study Group","year":"2004","unstructured":"US Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5:119\u201323.","journal-title":"Sleep Med"},{"key":"1150_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.sleep.2005.03.010","volume":"6","author":"Xyrem International Study Group","year":"2005","unstructured":"Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6:415\u201321.","journal-title":"Sleep Med"},{"key":"1150_CR36","first-page":"31","volume":"26","author":"US Xyrem Multicenter Study Group","year":"2003","unstructured":"US Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26:31\u20135.","journal-title":"Sleep"},{"key":"1150_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5664\/jcsm.26368","volume":"1","author":"Xyrem International Study Group","year":"2005","unstructured":"Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1:391\u20137.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR38","unstructured":"Jazz Pharmaceuticals. Xyrem\u00ae (sodium oxybate). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals, Inc; 2023."},{"key":"1150_CR39","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals, Inc. Release: Xyrem\u00ae Receives FDA approval for the treatment of excessive daytime sleepiness in patients with narcolepsy. 2005. https:\/\/www.biospace.com\/article\/releases\/jazz-pharmaceuticals-inc-release-xyrem-r-receives-fda-approval-for-the-treatment-of-excessive-daytime-sleepiness-in-patients-with-narcolepsy-\/. Accessed 15 July 2022."},{"key":"1150_CR40","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705\u201311.","journal-title":"Sleep"},{"key":"1150_CR41","unstructured":"Jazz Pharmaceuticals. Xywav\u2122 (calcium, magnesium, potassium, and sodium oxybate). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals, Inc; 2023."},{"key":"1150_CR42","doi-asserted-by":"publisher","first-page":"zsaa206","DOI":"10.1093\/sleep\/zsaa206","volume":"44","author":"RK Bogan","year":"2021","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44:zsaa206.","journal-title":"Sleep"},{"key":"1150_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1474-4422(21)00368-9","volume":"21","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022;21:53\u201365.","journal-title":"Lancet Neurol"},{"key":"1150_CR44","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.sleep.2020.09.017","volume":"75","author":"AY Avidan","year":"2020","unstructured":"Avidan AY, Kushida CA. The sodium in sodium oxybate: is there cause for concern? Sleep Med. 2020;75:497\u2013501.","journal-title":"Sleep Med"},{"key":"1150_CR45","doi-asserted-by":"publisher","first-page":"zsab200","DOI":"10.1093\/sleep\/zsab200","volume":"45","author":"CA Kushida","year":"2022","unstructured":"Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45:zsab200.","journal-title":"Sleep"},{"key":"1150_CR46","unstructured":"Avadel Pharmaceuticals. LUMRYZ\u2122 (sodium oxybate for extended-release oral suspension, CIII). Full Prescribing Information. Chesterfield: Avadel Pharmaceuticals; 2024."},{"key":"1150_CR47","doi-asserted-by":"publisher","first-page":"A197","DOI":"10.1093\/sleep\/zsab072.500","volume":"44","author":"D Canafax","year":"2021","unstructured":"Canafax D, Xiang W, Xiang JN. 501 Clinical PK of XW10172 for once nightly therapy in patients with narcolepsy or sleep disorders in neurodegenerative diseases. Sleep. 2021;44:A197\u20138.","journal-title":"Sleep"},{"key":"1150_CR48","unstructured":"Tris Pharma. Tris pharma announces development of a very low sodium and once-nightly oxybate formulation. 2021. https:\/\/www.trispharma.com\/who-we-are\/news-and-media\/tris-pharma-announces-development-of-a-very-low-sodium-and-once-nightly-oxybate-formulation. Accessed 2024."},{"key":"1150_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/NSS.S279345","volume":"14","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Bogan RK, Sonka K, et al. Calcium, magnesium, potassium, and sodium oxybates oral solution: a lower-sodium alternative for cataplexy or excessive daytime sleepiness associated with narcolepsy. Nat Sci Sleep. 2022;14:531\u201346.","journal-title":"Nat Sci Sleep."},{"key":"1150_CR50","unstructured":"Jazz Pharmaceuticals Inc. Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update. 2015. https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-and-concert-pharmaceuticals-provide-jzp-0. Accessed 23 Oct 2024."},{"key":"1150_CR51","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17:1881\u201393.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR52","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/ene.14888","volume":"28","author":"CLA Bassetti","year":"2021","unstructured":"Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28:2815\u201330.","journal-title":"Eur J Neurol"},{"key":"1150_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40801-020-00223-6","volume":"8","author":"MJ Strunc","year":"2021","unstructured":"Strunc MJ, Black J, Lillaney P, et al. The Xyrem\u00ae (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) program in the USA: results from 2016 to 2017. Drugs Real World Outcomes. 2021;8:15\u201328.","journal-title":"Drugs Real World Outcomes."},{"key":"1150_CR54","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module V\u2014risk management systems (Rev 2). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf. Accessed 17 Oct 2024."},{"key":"1150_CR55","unstructured":"UCB Pharma. XYREM (sodium oxybate). Summary of Product Characteristics. Brussels, Belgium: UCB Pharma; 2020."},{"key":"1150_CR56","unstructured":"European Medicines Agency. EU-Risk Management Plan for Xyrem\u00ae Sodium Oxybate 500 mg\/mL Oral Solution Version 10.1, Amsterdam. 2021."},{"key":"1150_CR57","doi-asserted-by":"publisher","first-page":"zsy128","DOI":"10.1093\/sleep\/zsy128","volume":"41","author":"G Mayer","year":"2018","unstructured":"Mayer G, Plazzi G, Iranzo A, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep. 2018;41:zsy128.","journal-title":"Sleep"},{"key":"1150_CR58","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.sleep.2017.03.028","volume":"35","author":"P Drakatos","year":"2017","unstructured":"Drakatos P, Lykouras D, D\u2019Ancona G, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80\u20134.","journal-title":"Sleep Med"},{"key":"1150_CR59","doi-asserted-by":"publisher","first-page":"A254","DOI":"10.1093\/sleep\/zsad077.0579","volume":"46","author":"T Stern","year":"2023","unstructured":"Stern T, Roy A, Shapiro C, et al. 0579 Long-term safety of once-nightly oxybate for narcolepsy: RESTORE study interim analysis of data. Sleep. 2023;46:A254\u20135.","journal-title":"Sleep"},{"key":"1150_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40801-023-00351-9","volume":"10","author":"J Gudeman","year":"2023","unstructured":"Gudeman J, Burroughs D. Evidence of accidental dosing errors with immediate-release sodium oxybate: data from the US Food and Drug Administration Adverse Event Reporting System. Drugs Real World Outcomes. 2023;10:225\u201334.","journal-title":"Drugs Real World Outcomes."},{"key":"1150_CR61","first-page":"137","volume":"19","author":"C Mayeux","year":"2023","unstructured":"Mayeux C, Sanders T, McIntosh B. Oxybate salts: acute respiratory failure from mistiming one night\u2019s doses. J Med Toxicol. 2023;19:137.","journal-title":"J Med Toxicol"},{"key":"1150_CR62","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/adb.12645","volume":"23","author":"W van den Brink","year":"2018","unstructured":"van den Brink W, Addolorato G, Aubin HJ, et al. Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addict Biol. 2018;23:969\u201386.","journal-title":"Addict Biol"},{"key":"1150_CR63","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/02698811221104063","volume":"36","author":"J Guiraud","year":"2022","unstructured":"Guiraud J, Addolorato G, Antonelli M, et al. Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: an international, multicenter, randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2022;36:1136\u201345.","journal-title":"J Psychopharmacol"},{"key":"1150_CR64","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/annrheumdis-2011-200418","volume":"71","author":"M Spaeth","year":"2012","unstructured":"Spaeth M, Bennett RM, Benson BA, et al. Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial. Ann Rheum Dis. 2012;71:935\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1150_CR65","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1517\/14656566.2011.589836","volume":"12","author":"R Staud","year":"2011","unstructured":"Staud R. Sodium oxybate for the treatment of fibromyalgia. Expert Opin Pharmacother. 2011;12:1789\u201398.","journal-title":"Expert Opin Pharmacother"},{"key":"1150_CR66","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1212\/WNL.0b013e31822313c6","volume":"77","author":"R Khatami","year":"2011","unstructured":"Khatami R, Tartarotti S, Siccoli MM, et al. Long-term efficacy of sodium oxybate in 4 patients with chronic cluster headache. Neurology. 2011;77:67\u201370.","journal-title":"Neurology"},{"key":"1150_CR67","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/head.12068","volume":"53","author":"H Hidalgo","year":"2013","unstructured":"Hidalgo H, Uhl V, Gantenbein AR, et al. Efficiency of sodium oxybate in episodic cluster headache. Headache. 2013;53:1490\u20131.","journal-title":"Headache"},{"key":"1150_CR68","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/jamaneurol.2017.3171","volume":"75","author":"F B\u00fcchele","year":"2018","unstructured":"B\u00fcchele F, Hackius M, Schreglmann SR, et al. Sodium oxybate for excessive daytime sleepiness and sleep disturbance in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75:114\u20138.","journal-title":"JAMA Neurol"},{"key":"1150_CR69","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.5664\/jcsm.9326","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17:1895\u2013945.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR70","doi-asserted-by":"crossref","unstructured":"During EH, Hernandez B, Miglis MG, et al. Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder. Sleep. 2023;46","DOI":"10.1093\/sleep\/zsad103"},{"key":"1150_CR71","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/0013-4694(88)90145-9","volume":"70","author":"R Broughton","year":"1988","unstructured":"Broughton R, Dunham W, Newman J, et al. Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls. Electroencephalogr Clin Neurophysiol. 1988;70:473\u201381.","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"1150_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.5664\/jcsm.7036","volume":"14","author":"E Hertenstein","year":"2018","unstructured":"Hertenstein E, Gabryelska A, Spiegelhalder K, et al. Reference data for polysomnography-measured and subjective sleep in healthy adults. J Clin Sleep Med. 2018;14:523\u201332.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR73","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/sleep\/17.7.590","volume":"17","author":"AE Rogers","year":"1994","unstructured":"Rogers AE, Aldrich MS, Caruso CC. Patterns of sleep and wakefulness in treated narcoleptic subjects. Sleep. 1994;17:590\u20137.","journal-title":"Sleep"},{"key":"1150_CR74","doi-asserted-by":"crossref","unstructured":"Maski KP, Colclasure A, Little E, et al. Stability of nocturnal wake and sleep stages defines central nervous system disorders of hypersomnolence. Sleep. 2021;44","DOI":"10.1093\/sleep\/zsab021"},{"key":"1150_CR75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ccm.2010.02.014","volume":"31","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med. 2010;31:371\u201381.","journal-title":"Clin Chest Med"},{"key":"1150_CR76","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/sleep\/27.7.1327","volume":"27","author":"M Mamelak","year":"2004","unstructured":"Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27:1327\u201334.","journal-title":"Sleep"},{"key":"1150_CR77","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.sleep.2023.12.015","volume":"114","author":"T Roth","year":"2023","unstructured":"Roth T, Dauvilliers Y, Bogan RK, et al. Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture. Sleep Med. 2023;114:255\u201365.","journal-title":"Sleep Med"},{"key":"1150_CR78","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-10-0913","volume":"164","author":"CE Donjacour","year":"2011","unstructured":"Donjacour CE, Aziz NA, Fr\u00f6lich M, et al. Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. Eur J Endocrinol. 2011;164:363\u201370.","journal-title":"Eur J Endocrinol"},{"key":"1150_CR79","doi-asserted-by":"publisher","first-page":"E1069","DOI":"10.1152\/ajpendo.00623.2010","volume":"300","author":"CE Donjacour","year":"2011","unstructured":"Donjacour CE, Aziz NA, Roelfsema F, et al. Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab. 2011;300:E1069\u201375.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1150_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNF.0b013e318203d415","volume":"34","author":"MK Alshaikh","year":"2011","unstructured":"Alshaikh MK, Gacuan D, George S, et al. Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem). Clin Neuropharmacol. 2011;34:1\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"1150_CR81","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000324549","volume":"65","author":"R Poryazova","year":"2011","unstructured":"Poryazova R, Tartarotti S, Khatami R, et al. Sodium oxybate in narcolepsy with cataplexy: Zurich sleep center experience. Eur Neurol. 2011;65:175\u201382.","journal-title":"Eur Neurol"},{"key":"1150_CR82","unstructured":"Tantrakul V, Guilleminault C. Effect of gammahydroxybutyrate on cyclic alternating pattern (CAP) in patients with narcolepsy with cataplexy. In: SLEEP 2011, The 25th anniversary meeting of the associated professional sleep societies; 2011 June 11\u201315; Minneapolis."},{"key":"1150_CR83","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.5665\/sleep.6220","volume":"39","author":"A van der Heide","year":"2016","unstructured":"van der Heide A, Werth E, Donjacour CE, et al. Core body and skin temperature in type 1 narcolepsy in daily life; effects of sodium oxybate and prediction of sleep attacks. Sleep. 2016;39:1941\u20139.","journal-title":"Sleep"},{"key":"1150_CR84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33588\/rn.7602.2022315","volume":"76","author":"R Peraita-Adrados","year":"2023","unstructured":"Peraita-Adrados R, Bellon JM, Lillo-Triguero L, et al. Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1. Rev Neurol. 2023;76:35\u201340.","journal-title":"Rev Neurol"},{"key":"1150_CR85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.sleep.2019.06.017","volume":"64","author":"XM Xu","year":"2019","unstructured":"Xu XM, Wei YD, Liu Y, Li ZX. Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis. Sleep Med. 2019;64:62\u201370.","journal-title":"Sleep Med"},{"key":"1150_CR86","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5664\/jcsm.27994","volume":"6","author":"J Black","year":"2010","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6:596\u2013602.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR87","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.5664\/jcsm.5.2S.S6","volume":"5","author":"DJ Dijk","year":"2009","unstructured":"Dijk DJ. Regulation and functional correlates of slow wave sleep. J Clin Sleep Med. 2009;5:S6-15.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR88","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.sleep.2022.09.011","volume":"100","author":"R Bogan","year":"2022","unstructured":"Bogan R, Thorpy MJ, Winkelman JW, et al. Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: phase 1 study in healthy volunteers. Sleep Med. 2022;100:442\u20137.","journal-title":"Sleep Med"},{"key":"1150_CR89","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.5664\/jcsm.9476","volume":"17","author":"K Ramar","year":"2021","unstructured":"Ramar K, Malhotra RK, Carden KA, et al. Sleep is essential to health: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2021;17:2115\u20139.","journal-title":"J Clin Sleep Med"},{"key":"1150_CR90","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.sleh.2023.07.016","volume":"9","author":"TL Sletten","year":"2023","unstructured":"Sletten TL, Weaver MD, Foster RG, et al. The importance of sleep regularity: a consensus statement of the National Sleep Foundation sleep timing and variability panel. Sleep Health. 2023;9:801\u201320.","journal-title":"Sleep Health"},{"key":"1150_CR91","unstructured":"Avadel CNS Pharmaceuticals, LLC. Data on File. Chesterfield: Avadel CNS Pharmaceuticals,, LLC; 2024."},{"key":"1150_CR92","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40263-022-00904-6","volume":"36","author":"T Roth","year":"2022","unstructured":"Roth T, Dauvilliers Y, Thorpy MJ, et al. Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase III REST-ON trial. CNS Drugs. 2022;36:377\u201387.","journal-title":"CNS Drugs"},{"key":"1150_CR93","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1111\/cts.13087","volume":"14","author":"C Chen","year":"2021","unstructured":"Chen C, Jenkins J, Zomorodi K, Skowronski R. Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies. Clin Transl Sci. 2021;14:2278\u201387.","journal-title":"Clin Transl Sci"},{"key":"1150_CR94","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/bcp.13204","volume":"83","author":"X Chen","year":"2017","unstructured":"Chen X, Broeyer F, de Kam M, et al. Pharmacodynamic response profiles of anxiolytic and sedative drugs. Br J Clin Pharmacol. 2017;83:1028\u201338.","journal-title":"Br J Clin Pharmacol"},{"key":"1150_CR95","unstructured":"Harmony Biosciences L. Wakix (pitolisant). Full Prescribing Information. Plymouth Meeting: Harmony Biosciences, LLC; 2024."},{"key":"1150_CR96","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.sleep.2024.09.024","volume":"124","author":"Y Dauvilliers","year":"2024","unstructured":"Dauvilliers Y, Roth T, Bogan R, et al. Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: a post hoc analysis from the phase 3 REST-ON trial. Sleep Med. 2024;124:209\u201316.","journal-title":"Sleep Med"},{"key":"1150_CR97","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0163-8343(90)90078-Q","volume":"12","author":"LD Rosenthal","year":"1990","unstructured":"Rosenthal LD, Merlotti L, Young DK, et al. Subjective and polysomnographic characteristics of patients diagnosed with narcolepsy. Gen Hosp Psychiatry. 1990;12:191\u20137.","journal-title":"Gen Hosp Psychiatry"},{"key":"1150_CR98","unstructured":"US Food and Drug Administration. Clinical superiority findings. 2023. https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings. Accessed 11 May 2023."},{"key":"1150_CR99","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3109\/07420528.2012.655869","volume":"29","author":"CE Donjacour","year":"2012","unstructured":"Donjacour CE, Kalsbeek A, Overeem S, et al. Altered circadian rhythm of melatonin concentrations in hypocretin-deficient men. Chronobiol Int. 2012;29:356\u201362.","journal-title":"Chronobiol Int"},{"key":"1150_CR100","doi-asserted-by":"publisher","first-page":"A182","DOI":"10.1093\/sleep\/zsac079.403","volume":"45","author":"M Thorpy","year":"2022","unstructured":"Thorpy M, Dauvilliers Y, Roth T, et al. 0406 Efficacy of once-nightly sodium oxybate (ON-SXB; FT218) across stimulant use subgroups: post-hoc analyses from the REST-ON trial. Sleep. 2022;45:A182.","journal-title":"Sleep"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01150-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:46:46Z","timestamp":1743497206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01150-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":100,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01150-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has been published as part of a journal supplement wholly funded by Avadel Pharmaceuticals (Chesterfield, MO, USA). Preparation of this manuscript was funded by Avadel Pharmaceuticals. Avadel Pharmaceuticals was involved in the writing of the manuscript and in the decision to submit for publication. Open access publication and publication costs were funded by Avadel Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas Roth is a consultant for Avadel Pharmaceuticals, Eisai, Idorsia, Jazz Pharmaceuticals, Merck & Co., Orexo, and Takeda Pharmaceutical Co.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Thomas Roth contributed to the conceptualization and refining of the review, analysis and interpretation, and writing of the original draft, as well as reviewing and editing the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}